Fig. 2: Impact of DAV132 12 g on the gut microbiome in healthy volunteers (HV). | Nature Communications

Fig. 2: Impact of DAV132 12 g on the gut microbiome in healthy volunteers (HV).

From: The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers

Fig. 2

A 16S rRNA microbiota profiling: mean change in α-diversity from baseline as measured by the Shannon Index in HV treated in CTRL, CZA, and CZA + DAV132 (left panel), and CTRL, PTZ, and PTZ + DAV132 (right panel) groups. AUC of change from baseline of the Shannon index until D16 were compared between arms using an ANOVA, followed by pairwise comparisons with a Tukey’s adjustment. B Bray–Curtis representation for beta diversity (β-diversity) between HV treated with CTRL, CZA, and CZA + DAV132 (upper panel) at D1, D6, D25, and D37, and in CTRL, PTZ, and PTZ + DAV132 (lower panel) at D1, D6, D16, and D37. Global and pairwise PERMANOVA were used to compare differences in β-diversity between groups. C Bray–Curtis distance measure between control and CZA or CZA + DAV132 at D1, D6, and D16 (upper panel) and between control and PTZ or PTZ + DAV132 (lower panel) at D1, D6, and D25. AUC area under the curve, CTRL control, CZA ceftazidime-avibactam, D day, ns not significant, PTZ piperacillin-tazobactam, DAV132, DAV132 12 g po tid. (ns non-significant, ****p < 0.0001). Source data are provided as a Source Data file.

Back to article page